首页> 外文OA文献 >Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation in Adults Using Fludarabine, Carmustine, Melphalan, and Antithymocyte Globulin: Outcomes Depend on Disease Risk Index but Not Age, Comorbidity Score, Donor Type, or Human Leukocyte Antigen Mismatch

【2h】

Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation in Adults Using Fludarabine, Carmustine, Melphalan, and Antithymocyte Globulin: Outcomes Depend on Disease Risk Index but Not Age, Comorbidity Score, Donor Type, or Human Leukocyte Antigen Mismatch

机译：使用氟达拉滨，卡莫司汀，美法仑和抗胸腺细胞球蛋白降低成人的毒性条件和同种异体干细胞移植：结果取决于疾病风险指数，但不取决于年龄，合并症评分，供体类型或人类白细胞抗原不匹配

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Slack James L.; Dueck Amylou C.; Fauble Veena D.; Sproat Lisa O.; Reeder Craig B.; Noel Pierre; Khera Nandita; Betcher Jeffery A.; Klein Jared L.; Leis Jose F.; Adams Roberta H.;
展开▼
作者单位

展开▼
年度 2013
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using Fludarabine, Carmustine, Melphalan, and Antithymocyte Globulin: Outcomes depend on disease risk index but not age, Comorbidity score, donor type, or human Leukocyte Antigen mismatch [J] . SlackJ.L., DueckA.C., FaubleV.D., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2013,第8期

机译：使用氟达拉滨，卡莫司汀，美法仑和抗胸腺细胞球蛋白降低成人的毒性条件和同种异体干细胞移植：结果取决于疾病风险指数，但不取决于年龄，合并症评分，供体类型或人白细胞抗原失配
2. Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study [J] . Hamidieh A. A., Behfar M., Pourpak Z., Bone marrow transplantation . 2016,第2期

机译：氟达拉滨，美法仑和抗胸腺细胞球蛋白作为原发性免疫缺陷疾病儿童同种异体造血干细胞移植低强度调节方案的长期结果：一项前瞻性单中心研究
3. Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome [J] . Wais V., Kuendgen L., Bohl S. R., Bone marrow transplantation . 2018,第1期

机译：使用Fludarabine，BCNU和Melphalan的老年人或可嗜血症患者的同种异体造血细胞移植的减少毒性调理：移植疾病阶段决定了结果
4. Fludarabine Phosphete and Melphalan - An Immunosuppressive Reduced Intensity Conditioning (RIC) Regimen for AUogeneic Stem Cell Transplantation in Patients with a Range of Hematological Malignancies [C] . G. Jackson, C. Richardson, G. Morgan, European Haematology Association . 2002

机译：Fludarabine phospete和Melphalan - 一种免疫抑制性降低的强度调理（RIC）治疗患者血液学恶性肿瘤患者的促孕酮干细胞移植方案
5. Pre-Transplant Risk Factors Associated With Worse Outcomes in Adolescents and Young Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [D] . Friend, Brian. 2018

机译：与经历同种异体造血干细胞移植的青少年和青少年较差的预移植危险因素
6. Experience with Alemtuzumab Fludarabine and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease Stem Cell Source and Alemtuzumab Regimen [O] . Rebecca A. Marsh, Marepalli B. Rao, Aharon Gefen, -1

机译：在非恶性疾病患者中使用Alemtuzumab氟达拉滨和美法仑降低强度的条件进行造血细胞移植的经验显示出良好的结果并且混合嵌合体的风险取决于基础疾病干细胞来源和Alemtuzumab方案
7. Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome [O] . V Wais, L Kündgen, S R Bohl, 2017

机译：使用Fludarabine，BCNU和Melphalan的老年人或可嗜血症患者的同种异体造血细胞移植的减少毒性调理：移植疾病阶段决定了结果

Reduced Toxicity Conditioning and Allogeneic Stem Cell Transplantation in Adults Using Fludarabine, Carmustine, Melphalan, and Antithymocyte Globulin: Outcomes Depend on Disease Risk Index but Not Age, Comorbidity Score, Donor Type, or Human Leukocyte Antigen Mismatch

著录项

相似文献

相关主题

期刊订阅